ArticleHuman cell2022
RBPMS2, as a novel biomarker for predicting lymph node metastasis, guides therapeutic regimens in gastric cancer.
Article in Human cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Multi-regional feature integration on enhanced CT for lymph node metastasis prediction in gastric cancer: a novel radiomics approach.BMC medical imaging · 2025Article
- Identification of prognostic biomarkers and development of a prediction model for prostate cancer.Frontiers in immunology · 2025Article
- O-GlcNAcylation-related genes mediate tumor microenvironment characteristics and prediction of immunotherapy response in gastric cancer.Acta biochimica et biophysica Sinica · 2024Article
- Co-expression pattern of SLC transporter genes associated with the immune landscape and clinical outcomes in gastric cancer.Journal of cellular and molecular medicine · 2023Article
- DNA methylation of RNA-binding protein for multiple splicing 2 functions as diagnosis biomarker in gastric cancer pathogenesis and its potential clinical significance.Bioengineered · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
RNA-binding protein with multiple splicing 2 (RBPMS2) is a critical gene that encodes a member of the RNA-recognition-motif-containing protein family and is involved in the development and dedifferentiation of digestive smooth muscle cells. However, whether RBPMS2 has an effect on the prognosis of gastric cancer (GC) and its possible mechanism during GC progression remain unknown. Here, we collected 596 GC patients who underwent curative surgical resection to evaluate expression of RBPMS2. RBPMS2 was upregulated in GC tissues, and was associated with lymph node metastasis. We analysis the KEGG pathway and GO biological processes, cellular component and molecular function of RBPMS2 interactive genes, as well as RBPMS2-binding partner ESRP1 interactive genes. We also focus on the correlation analysis between EMT-related genes and RBPMS2/ESRP1. Finally, we analysed the correlation between RBPMS2 expression and chemotherapeutic drugs which may assist in GC therapy and demonstrated that RBPMS2 expression was associated with tumour mutation burden (TMB) and Microsatellite Instability (MSI), as well as immune infiltration level in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.